Literature DB >> 26643821

Impact of the Right Ventricular Lead Position on Clinical End Points in CRT Recipients--A Subanalysis of the Multicenter Randomized SPICE Trial.

Stefan Asbach1, Carsten Lennerz2, Verena Semmler2, Christian Grebmer2, Ulrich Solzbach3, Axel Kloppe4, Norbert Klein5, Istvan Szendey6, George Andrikopoulos7, Stylianos Tzeis7, Christoph Bode1, Christof Kolb.   

Abstract

BACKGROUND: The impact of right ventricular (RV) lead location on clinical end points in patients undergoing cardiac resynchronization therapy (CRT) is unclear. We evaluated the impact of different RV lead locations on clinical outcome in CRT patients enrolled in the Septal Positioning of ventricular implantable cardioverter-defibrillator (ICD) Electrodes (SPICE) trial, which randomized recipients of implantable cardioverter defibrillators to apical versus midseptal RV lead positioning.
METHODS: Ninety-eight CRT recipients were included in the multicenter SPICE trial and followed for 12 months: Fifty-three patients were randomized to receive an apical (A) and 45 to receive a midseptal (S) lead position. We compared echocardiographical and electrocardiographical parameters and outcome.
RESULTS: Echocardiographic response with respect to improvement of left ventricular ejection fraction (A: +15.8 ± 14.6%, S: +9.7 ± 12.6%, P = 0.156) and reduction of left ventricular end-diastolic diameter (A: -4.2 ± 10.7 mm, S: -7.5 ± 10.7 mm, P = 0.141) was comparable in apical and midseptal groups. Paced QRS width neither differed at prehospital discharge (A: 129 ± 21 ms, S: 135 ± 21 ms, P = 0.133) nor at 12-month follow-up (A: 131 ± 23 ms, S: 134 ± 28 ms, P = 0.620). No differences were found with respect to the risk of ventricular tachyarrhythmia or ICD therapy. Septal RV lead position, however, was associated with a significant longer time to a first heart failure event (P = 0.040) and a longer survival time (P = 0.019).
CONCLUSIONS: In CRT recipients, midseptal RV lead position was not superior with respect to improvement of echocardiographic parameters or paced QRS width. It did not predispose to ventricular arrhythmias or ICD therapy. The finding that midseptal lead position was associated with a longer time to first heart failure event and a longer survival time deserves further investigation.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  arrhythmias; cardiac resynchronization therapy; heart failure; right ventricular lead position

Mesh:

Year:  2016        PMID: 26643821     DOI: 10.1111/pace.12793

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  5 in total

1.  Right ventricular lead location, right-left ventricular lead interaction, and long-term outcomes in cardiac resynchronization therapy patients.

Authors:  Usama A Daimee; Helmut U Klein; Michael C Giudici; Wojciech Zareba; Scott McNitt; Bronislava Polonsky; Arthur J Moss; Valentina Kutyifa
Journal:  J Interv Card Electrophysiol       Date:  2018-03-23       Impact factor: 1.900

2.  Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis.

Authors:  Fatima Ali-Ahmed; Frederik Dalgaard; Nancy M Allen Lapointe; Andrzej S Kosinski; Vanessa Blumer; Daniel P Morin; Gillian D Sanders; Sana M Al-Khatib
Journal:  Prog Cardiovasc Dis       Date:  2021-04-20       Impact factor: 8.194

3.  Clinical and echocardiographic response of apical vs nonapical right ventricular lead position in CRT: A meta-analysis.

Authors:  Sharan Prakash Sharma; Khagendra Dahal; Paari Dominic; Rajbir S Sangha
Journal:  J Arrhythm       Date:  2018-03-13

4.  Contractility surrogates derived from three-dimensional lead motion analysis and prediction of acute haemodynamic response to CRT.

Authors:  Stian Ross; Hans Henrik Odland; Trent Fischer; Thor Edvardsen; Lars Ove Gammelsrud; Trine Fink Haland; Richard Cornelussen; Einar Hopp; Erik Kongsgaard
Journal:  Open Heart       Date:  2018-12-10

5.  Influence of the Right Ventricular Lead Location on Ventricular Arrhythmias in Cardiac Resynchronization Therapy.

Authors:  Hao Su; Pei Bao; Kang-Yu Chen; Ji Yan; Jian Xu; Fei Yu; Dong-Mei Yang
Journal:  Chin Med J (Engl)       Date:  2018-10-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.